CCR2 and metabolic dysfunction-associated steatohepatitis: Currently the phase 2b multinational clinical trial (CENTAUR) is underway to evaluate the anti-inflammatory and anti-fibrotic potential of a dual CCR2/CCR5 antagonist Cenicriviroc (CVC) in patients with NASH[10].